

THOMPSON STREET

CAPITAL PARTNERS

THOMPSON STREET CAPITAL PARTNERS PORTFOLIO COMPANY BIORECLAMATIONIVT ACQUIRES QUALYST TRANSPORTER SOLUTIONS, LLC

ST. LOUIS (September 7, 2017) – Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, announced today that its portfolio company BioreclamationIVT has acquired Durham, North Carolina-based Qualyst Transporter Solutions, LLC, (Qualyst) provider of *in vitro* hepatic models and services that predict the effect of drugs and other compounds on the human liver. Terms of the transaction were not disclosed.

Qualyst (www.qualyst.com) uses a unique cell-based testing approach to predict compound clearance, drug-drug interactions, and toxicity in the human liver, for the pharmaceutical, chemical, consumer products, and cosmetics industries. The Company's Transporter Certified™ hepatocyte program, now an industry standard, ensures that cells, under defined culture conditions, maintain physiologic transporter uptake and efflux levels which are critical for normal function.

###